Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vernalis Considers US Deals As Prescription Cough/Cold Strategy Delivers

This article was originally published in The Pink Sheet Daily

Executive Summary

Vernalis launches its first long-acting liquid cough and cold product, Tuzistra XR, in the US as part of a revised business focus on generating sustainable revenues from low development risk, late-stage products.

Advertisement

Related Content

Vernalis Raises $100 million To Support Push Into U.S. Rx Cough/Cold Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078971

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel